Medical products company UFP Technologies (NASDAQ:UFPT) will be reporting earnings tomorrow before market hours. Here’s what to look for.

UFP Technologies beat analysts’ revenue expectations by 1.7% last quarter, reporting revenues of $144.1 million, up 41.9% year on year. It was a strong quarter for the company, with a decent beat of analysts’ EPS estimates.

Is UFP Technologies a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting UFP Technologies’s revenue to grow 33.3% year on year to $139.9 million, improving from the 7.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.01 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. UFP Technologies has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 5.1% on average.

Looking at UFP Technologies’s peers in the drug development inputs & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 9.3%, beating analysts’ expectations by 6%, and West Pharmaceutical Services reported flat revenue, topping estimates by 2%. Medpace traded down 2.1% following the results while West Pharmaceutical Services was also down 1.6%.

Read our full analysis of Medpace’s results here and West Pharmaceutical Services’s results here.

There has been positive sentiment among investors in the drug development inputs & services segment, with share prices up 4.9% on average over the last month. UFP Technologies is up 2.6% during the same time and is heading into earnings with an average analyst price target of $381 (compared to the current share price of $202.21).

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.